Molecular Biomarkers Predict Steroid Response in Keloids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for keloids lack a reliable molecular test to predict patient response to steroid therapy, leading to variable and often ineffective treatments with high recurrence rates.
Innovation Solution
An unbiased transcriptomic approach using RNA sequencing identifies specific gene expression patterns in keloid cells to determine steroid responsiveness, allowing for the development of a rapid molecular test to predict patient response to steroid therapy by measuring the expression levels of MCAM, WFDC1, IGFBP2, EYA4, and IGF1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intralesional steroid injections are used for keloid therapy, then treatment is provided for keloid lesions, but patient response varies widely and recurrence rates remain high due to inability to predict responsiveness
Solution Approach 1:
The patent performs gene expression analysis on keloid tissue samples before initiating steroid therapy to predict patient responsiveness. This preliminary molecular characterization allows clinicians to identify which patients are likely to respond to steroid treatment versus those who will not, enabling informed treatment selection before therapy begins.
Solution Approach 2:
The patent introduces molecular biomarkers (specific gene expression profiles) as intermediaries between the patient's keloid tissue and the steroid treatment decision. These biomarkers serve as mediators that translate complex biological variability into actionable predictive information, allowing objective treatment selection without requiring complex clinical judgment.
2Ease of operation
If steroid therapy is administered without molecular testing, then treatment can be initiated immediately, but adverse effects occur and compliance decreases due to ineffective treatment
Solution Approach 1:
The patent performs rapid gene expression analysis on keloid tissue samples before initiating steroid therapy to predict patient responsiveness. This preliminary molecular characterization allows clinicians to identify which patients are likely to respond to steroid treatment versus those who will not, enabling informed treatment selection before therapy begins.
Solution Approach 2:
The patent prevents adverse effects by identifying non-responders before steroid therapy is administered. By detecting gene expression profiles indicative of steroid resistance in advance, the system prevents unnecessary steroid exposure and associated adverse effects in patients who would not benefit from the treatment.
3Measurement precision
If molecular testing is performed to predict steroid responsiveness, then personalized treatment decisions can be made, but testing time and complexity increase
Solution Approach 1:
The patent extracts and analyzes specific gene expression markers from keloid tissue samples to predict steroid responsiveness. By focusing on a targeted set of molecular biomarkers rather than comprehensive genomic analysis, the method achieves accurate prediction while minimizing testing time and complexity.
Data Source
AI summary
The invention concerns molecular biomarkers useful for screening individuals for steroid resistance and steroid sensitivity in the selection of treatments for keloids and other conditions. Aspects of the invention include a method for determining whether or not an individual will respond beneficially to a steroid therapy; a method for selecting a therapy for an individual having a condition, using the screening method; a method for treating a condition of an individual, using the screening method; and a detection device useful for detecting expression levels of the biomarkers.